These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 14632547)

  • 21. Prevention of venous thromboembolism among hospitalized medical patients.
    Goldhaber SZ; Turpie AG
    Circulation; 2005 Jan; 111(1):e1-3. PubMed ID: 15630031
    [No Abstract]   [Full Text] [Related]  

  • 22. Thromboembolism.
    Fitzmaurice D; Hobbs FR; McManus R
    Clin Evid; 2005 Dec; (14):198-215. PubMed ID: 16620405
    [No Abstract]   [Full Text] [Related]  

  • 23. Low-molecular-weight heparin in pediatric patients.
    Sutor AH; Chan AK; Massicotte P
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():31-9. PubMed ID: 15085464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of venous thromboembolism in hospitalized medical patients.
    Lenchus JD; Jaffer AK
    Mt Sinai J Med; 2008 Oct; 75(5):449-53. PubMed ID: 18828167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of venous thromboembolism after ischemic stroke.
    Kase CS; Pineo GF
    Curr Opin Pulm Med; 2008 Sep; 14(5):389-96. PubMed ID: 18664967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thromboembolism.
    Fitzmaurice D; Hobbs FR; McManus R
    Clin Evid; 2003 Dec; (10):273-88. PubMed ID: 15555092
    [No Abstract]   [Full Text] [Related]  

  • 27. Thromboembolism.
    Fitzmaurice D; Hobbs FD; McManus R
    Clin Evid; 2004 Dec; (12):285-308. PubMed ID: 15865639
    [No Abstract]   [Full Text] [Related]  

  • 28. Laboratory monitoring of anticoagulation: where do we stand?
    Tripodi A; van den Besselaar A
    Semin Thromb Hemost; 2009 Feb; 35(1):34-41. PubMed ID: 19308891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proceedings of a symposium on Fluxum (low molecular weight heparin): a new prophylactic and therapeutic approach to thromboembolic diseases. Held during the 1st Mediterranean Congress of Angiology. Corfu, Greece, June 2, 1988.
    Int Angiol; 1988; 7(3 Suppl):1-47. PubMed ID: 2850321
    [No Abstract]   [Full Text] [Related]  

  • 30. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Heparin and cancer].
    Lykke J
    Ugeskr Laeger; 2006 Dec; 168(50):4397-401. PubMed ID: 17217864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery.
    Bergqvist D
    Br J Surg; 2004 Aug; 91(8):965-74. PubMed ID: 15286956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.
    Pineo GF; Hull RD
    Eur J Med Res; 2004 Apr; 9(4):215-24. PubMed ID: 15210402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-molecular-weight heparin for thromboprophylaxis.
    Camporese G; Bernardi E
    Curr Opin Pulm Med; 2009 Sep; 15(5):443-54. PubMed ID: 19593139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New anticoagulant drugs: a critical perspective.
    Haas S
    Curr Hematol Rep; 2005 Sep; 4(5):335-8. PubMed ID: 16131432
    [No Abstract]   [Full Text] [Related]  

  • 36. [Assessing the use of low-molecular-weight heparins fo venous thromboembolism prophylaxis in internal medicine patients].
    Villar Fernández I; Urbieta Sanz E; Arenere Mendoza M; López Larramona G; Marcilla Córdoba F; Rabanaque Hernández MJ
    Farm Hosp; 2004; 28(6):402-9. PubMed ID: 15628942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Low-molecular-weight heparins versus unfractionated heparin for treatment of hemodialysed patients].
    Kes P; Basić-Jukić N; Jurić I
    Lijec Vjesn; 2007; 129(8-9):305-8. PubMed ID: 18198633
    [No Abstract]   [Full Text] [Related]  

  • 38. [Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles].
    Alban S
    Hamostaseologie; 2008 Feb; 28(1-2):51-61. PubMed ID: 18278163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is unfractionated heparin equivalent to low-molecular-weight heparin for venous thromboembolism?
    Graber MA; Dachs R; Darby-Stewart A
    Am Fam Physician; 2008 Jun; 77(11):1492-3. PubMed ID: 18581828
    [No Abstract]   [Full Text] [Related]  

  • 40. The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients.
    Noble SI; Hood K; Finlay IG
    Palliat Med; 2007 Sep; 21(6):473-6. PubMed ID: 17846086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.